Article
Transplantation
Hirohito Goto, Ken Iseri, Noriko Hida
Summary: This nested case-control study investigated the efficacy of fibrates on the risk of major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD). The results showed that recent and current use of fibrates, especially pemafibrate, was associated with a reduced risk of MACE in CKD patients.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Pharmacology & Pharmacy
Jian-Jun Li, Ke-Fei Dou, Zhi-Guang Zhou, Dong Zhao, Ping Ye, Jia-Jun Zhao, Li-Xin Guo
Summary: Low-density lipoprotein cholesterol (LDL-C) has been the main target for preventing and treating atherosclerotic cardiovascular disease (ASCVD). However, some patients still have residual cardiovascular risks even when LDL-C reaches the target level. Emerging evidence suggests that elevated triglyceride (TG) level is an important component of the residual cardiovascular risks. Omega-3 fatty acids are effective in reducing TG, but their efficacy in reducing the risk of ASCVD is inconsistent in large randomized clinical trials. Experts have a lack of consensus on the application of omega-3 fatty acids in cardiovascular diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Ronald M. Goldenberg, Alice Y. Y. Cheng, Jeremy D. Gilbert, Eva M. Lonn, Sue D. Pedersen, Subodh Verma
Summary: High triglyceride levels are associated with heightened cardiovascular risk, despite LDL-C levels and statin therapy. The REDUCE-IT trial with IPE demonstrated reduced cardiovascular risk in individuals with preexisting atherosclerotic cardiovascular disease or diabetes.
CURRENT OPINION IN CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Andrew P. Ambrosy, Jingrong Yang, Sue Hee Sung, Amanda R. Allen, Jesse K. Fitzpatrick, Jamal S. Rana, Jeffrey Wagner, Sephy Philip, David Abrahamson, Craig Granowitz, Alan S. Go
Summary: The study found that in patients receiving statin therapy, elevated triglyceride levels were associated with a higher risk of atherosclerotic cardiovascular disease events and a lower risk of death.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Pharmacology & Pharmacy
M. John Chapman, Jose L. Zamorano, Klaus G. Parhofer
Summary: Atherosclerotic cardiovascular disease (ASCVD) imposes a significant burden on Europe, and hypertriglyceridemia is a major risk factor for premature ASCVD. Recent studies have shown a correlation between elevated triglyceride levels and subclinical atherosclerosis and arterial inflammation. Icosapent ethyl (IPE) is a drug that can reduce the risk of cardiovascular events in patients with high triglyceride levels, possibly through triglyceride reduction and improvement of vascular function.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Henry N. Ginsberg, Chris J. Packard, M. John Chapman, Jan Boren, Carlos A. Aguilar-Salinas, Maurizio Averna, Brian A. Ference, Daniel Gaudet, Robert A. Hegele, Sander Kersten, Gary F. Lewis, Alice H. Lichtenstein, Philippe Moulin, Borge G. Nordestgaard, Alan T. Remaley, Bart Staels, Erik S. G. Stroes, Marja-Riitta Taskinen, Lale S. Tokgozoglu, Anne Tybjaerg-Hansen, Jane K. Stock, Alberico L. Catapano
Summary: This article reviews the impact of triglycerides and triglyceride-rich lipoproteins on cardiovascular disease risk, emphasizing that reducing levels of TRL and their remnants can help reduce the risk of ASCVD.
EUROPEAN HEART JOURNAL
(2021)
Article
Multidisciplinary Sciences
Sigri Bakken Sperstad, Julie Caroline Saether, Marie Klevjer, Guro Fannelob Giskeodegard, Tone Frost Bathen, Ragnhild Rosbjorgen, Havard Dalen, Anja Bye
Summary: The study found that lipoprotein subfractions are closely associated with the risk of MI, especially in males. However, after adjusting for multiple testing, none of the lipoprotein subfractions were significantly associated with future MI.
Article
Cardiac & Cardiovascular Systems
Henry N. Ginsberg, Chris J. Packard, M. John Chapman, Jan Boren, Carlos A. Aguilar-Salinas, Maurizio Averna, Brian A. Ference, Daniel Gaudet, Robert A. Hegele, Sander Kersten, Gary F. Lewis, Alice H. Lichtenstein, Philippe Moulin, Borge G. Nordestgaard, Alan T. Remaley, Bart Staels, Erik S. G. Stroes, Marja-Riitta Taskinen, Lale S. Tokgozoglu, Anne Tybjaerg-Hansen, Jane K. Stock, Alberico L. Catapano
Summary: Recent research supports a causal association between triglycerides, triglyceride-rich lipoproteins, and their remnants with cardiovascular diseases, emphasizing the importance of focusing on their impact on heart health. Targeting levels of triglycerides and their remnants may potentially reduce the risk of atherosclerotic cardiovascular diseases.
EUROPEAN HEART JOURNAL
(2021)
Article
Genetics & Heredity
Elisabeth A. Rosenthal, David R. Crosslin, Adam S. Gordon, David S. Carrell, Ian B. Stanaway, Eric B. Larson, Jane Grafton, Wei-Qi Wei, Joshua C. Denny, Qi-Ping Feng, Amy S. Shah, Amy C. Sturm, Marylyn D. Ritchie, Jennifer A. Pacheco, Hakon Hakonarson, Laura J. Rasmussen-Torvik, John J. Connolly, Xiao Fan, Maya Safarova, Iftikhar J. Kullo, Gail P. Jarvik
Summary: Analyzing a mixed-ancestry cohort, associations between several genes and triglyceride levels were replicated, while associations with other genes were not replicated due to limited sample size and missing drug information. Challenges exist in using electronic health record data for analysis.
BMC MEDICAL GENOMICS
(2021)
Review
Immunology
Carlos Zamora, Elisabet Canto, Silvia Vidal
Summary: Patients with chronic inflammatory diseases often have cardiovascular risks due to persistent systemic inflammation and endothelial activation. Activated platelets are considered major players in this inflammation, although their role has become controversial in recent years. Platelets can release both pro- and anti-inflammatory mediators and modulate the function of circulating lymphocytes, monocytes, and neutrophils, but how they exert this dual role is not fully understood.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Endocrinology & Metabolism
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Summary: This study investigated the effects of fenofibrate add-on to statin treatment on all-cause death and cardiovascular disease (CVD) in the general population with high triglyceride (TG) levels. The research found that the use of fenofibrate was associated with a lower incidence of all-cause death and CVD in individuals with high TG, regardless of the presence of diabetes. However, the beneficial effects required at least one year of fenofibrate use.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Review
Peripheral Vascular Disease
Emir Muzurovic, Carol Chiung-Hui Peng, Matthew J. Belanger, Despina Sanoudou, Dimitri P. Mikhailidis, Christos S. Mantzoros
Summary: The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, and it is associated with an increased risk of cardiovascular disease (CVD). The two conditions share several risk factors, such as obesity, metabolic syndrome, and type 2 diabetes. Personalized therapeutic approaches and public health policies are needed to effectively address the NAFLD epidemic.
Review
Cell Biology
Giulia Germena, Laura Cecilia Zelarayan, Rabea Hinkel
Summary: Exosomes are small membranous vesicles that contain biological material and can mediate cell-to-cell communication, maintaining homeostasis or modulating disease processes. They play a crucial role in cardiovascular diseases and have potential diagnostic value, although their specific physiological and pathophysiological functions in the cardiovascular system are still not fully understood.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Nutrition & Dietetics
AlMa Mihaela Dimache, Delia Lidia Salaru, Radu Sascau, Cristian Statescu
Summary: The burden of cognitive disorders is substantial and varies in etiology and severity. Triglyceride levels may be associated with cognitive function, but not all studies have found this link. Further research is needed to evaluate the relationship between triglycerides and cognitive impairment.
Review
Medicine, Research & Experimental
Katherine A. Maki, Sukirth M. Ganesan, Brianna Meeks, Nicole Farmer, Narjis Kazmi, Jennifer J. Barb, Paule V. Joseph, Gwenyth R. Wallen
Summary: This review examines the association between smoking and the oral microbiome, as well as smoking and cardiovascular risk/disease, and explores potential mechanisms. The findings suggest that certain oral bacteria are correlated with smoking, and these bacteria are also associated with cardiovascular outcomes.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
